RT Book, Section
A1 Murri, PharmD, MBA, Chief of Pharmacy, Jonathan M. Wainwright Memorial VA Medical Center, Clinical Assistant Professor, University of Washington School of Pharmacy, Nelda
A2 Brunton, Laurence L.
A2 Knollmann, Björn C.
SR Print(0)
ID 1198878158
T1 The Goodman & Gilman Year in Review: 2014 New and Noteworthy FDA Approvals
T2 Goodman & Gilman's: The Pharmacological Basis of Therapeutics, 14th Edition
YR 2023
FD 2023
PB McGraw-Hill Education
PP New York, NY
SN 9781264258079
LK hemonc.mhmedical.com/content.aspx?aid=1198878158
RD 2024/04/16
AB The  FDA  approved  54  new  drugs  and  biologics  of  note  in  2014.  Thirty-four  new  drugs  are  pharmacologically  similar  to  others  already  marketed  (see  Part  2  of  this  chapter).  The  remaining  20  represent  first-in-class  agents  indicated  for  the  management  of  cancers,  cardiovascular  risk,  hepatitis  C  virus  (HCV)  infection,  insomnia,  inflammatory  bowel  disease,  leishmaniasis,  lipodystrophy,  mucopolysaccharidosis,  onychomycosis,  and  pulmonary  fibrosis,  and  for  immunization  against  serogroup  B  meningococcal  disease  (eTable  1).